Benevolent Platform Precision Medicine slide image

Benevolent Platform Precision Medicine

Both the Ulcerative Colitis and Crohn's Disease markets are large, and expected to experience sizable growth USD Millions USD Millions Ulcerative Colitis Market Size, 2019-2029, 7MM(1) 14000 12000 10000 8000 6000 4000 2000 0 6.1% CAGR 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Crohn's Disease Market Size, 2019-2029, 7MM (2) 14000 12000 10000 8000 6000 4000 5.6% CAGR • Taken together, the 2019 UC and CD market sizes were valued at approx. $14B across the 7 major markets, expected to increase to approx $24B in total by 2029, growing at a ~6% CAGR Growth in the UC and CD markets is driven by: Improved diagnosis and increasing prevalence O Approval of numerous pipeline drugs (both small molecules and biologics) High treatment rates High unmet need for safe & efficacious therapies • Despite a competitive pipeline, there is opportunity to differentiate BEN- 8744 as an oral small molecule with a novel MoA based on safety, efficacy and through pursuing a precision medicine approach 2000 0 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Source: (1) Global Data, Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2029: (2) GlobalData, Crohn's Disease: Global Drug Forecast and Market Analysis to 2029. 7MM (7 Major Markets): EU5, US, Japan AI Benevolent 39
View entire presentation